External validation of the albumin, C-reactive protein and lactate dehydrogenase model in patients with metastatic renal cell carcinoma receiving second-line axitinib therapy in a Japanese multi-center cohort
| Autor: | Yasutomo Nakai, Motokiyo Komiyama, Naohisa Kusakabe, Motohide Uemura, Mikio Sugimoto, Satoshi Anai, Keita Tamura, Nobuo Shinohara, Kosuke Ueda, Ken Tanaka, Keita Minami, Kojiro Ohba, Tetsuya Shindo, Michinobu Ozawa, Naoki Kohei, Toshihiro Suzuki, Takahiro Osawa, Hideaki Miyake, Ario Takeuchi, Akira Yokomizo |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Male
Oncology Cancer Research medicine.medical_specialty Axitinib medicine.medical_treatment Urologic Oncology Antineoplastic Agents Targeted therapy Cohort Studies 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Japan Risk Factors Renal cell carcinoma Albumins Lactate dehydrogenase Internal medicine medicine Humans Radiology Nuclear Medicine and imaging 030212 general & internal medicine Carcinoma Renal Cell Aged L-Lactate Dehydrogenase biology business.industry C-reactive protein Albumin Cancer General Medicine Middle Aged Prognosis medicine.disease Kidney Neoplasms C-Reactive Protein chemistry 030220 oncology & carcinogenesis biology.protein Female business medicine.drug |
| Zdroj: | Japanese Journal of Clinical Oncology. 51:810-818 |
| ISSN: | 1465-3621 |
| Popis: | Purpose To externally validate the utility of the albumin, C-reactive protein and lactate dehydrogenase model to predict the overall survival of previously treated metastatic renal cell carcinoma patients. Patients and methods The ability of the albumin, C-reactive protein and lactate dehydrogenase model to predict overall survival was validated and compared with those of other prognostication models using data from 421 metastatic renal cell carcinoma patients receiving second-line axitinib therapy at 36 hospitals belonging to the Japan Urologic Oncology Group. Results The following factors in this cohort were independently associated with poor overall survival in a multivariate analysis: a low Karnofsky performance status, 50%. The superiority of the albumin, C-reactive protein and lactate dehydrogenase model to the Memorial Sloan Kettering Cancer Center and International Metastatic Renal Cell Carcinoma Database Consortium models, but not the Japan Urologic Oncology Group model, was demonstrated by multiple statistical analyses. Conclusions The utility of the albumin, C-reactive protein and lactate dehydrogenase model as a simple and objective prognostication tool was successfully validated using data from 421 metastatic renal cell carcinoma patients receiving second-line axitinib. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|